"Network pharmacology: systematic drug discovery"
| About Us |
 |
 |
|
e-Therapeutics is a drug discovery and development company. The company possesses efficient patented methods for discovering new bioactive compounds, de-risking candidates against efficacy and safety, discovering combinations of compounds with specific therapeutic effects, and discovering surprising new indications for existing compounds. E-Therapeutics has led the development of Network Pharmacology since its formation in 2001. Systematic Drug DiscoveryScientific advances in complex systems science at Oxford and Newcastle Universities led to the foundation of e-Therapeutics. Our scientists derived methods for untangling complex biological networks to show their functional structure, and methods for accurately predicting and explaining the effects of multiple interventions in any complex network. Multiple interventions often cause highly counterintuitive, difficult-to-predict effects, such as the bizarre “paradoxical restorations of function” in neurology, and apparent unpredictability in drug discovery and development.The application of these methods to drug discovery began in 2003. Almost all the processes that underlie life and disease are mediated by complex networks of interaction between proteins and other molecules. e-Therapeutics’ methods are a powerful platform for understanding what the structure of these networks means for function, dysfunction and mitigation. In addition, it is now clear that drug molecules affect multiple proteins and not just their primary target. Because of these multiple interventions in complex networks, the biological effects of a molecule's interactions with pathogenic, pathological and normal cells have historically been very difficult to predict. The consequence of this poor predictability has been unsustainably high clinical stage attrition, and very low and decreasing productivity in conventional drug discovery programmes. e-Therapeutics’ quantitative methods for calculating the net effect of a molecule’s multiple interventions in the networks within very many different cell-types enables a new approach to evaluating the efficacy and safety of molecules very early in development, and a new approach to discovering molecules that bring benefit to patients who are poorly treated by current medicines. |
Latest News
Dr Daniel Elger will present an overview of the Company's strategy, platform and clinical development programmes at the 14th Annual BIO CEO & Investor Conference in New York on Monday 13 February at 2.00 pm EST (1900 BST). Click here for the webcast of the presentation.
|
e-Therapeutics PLC
Holland Park,
Holland Drive,
Newcastle upon Tyne,
NE2 4LZ
| Terms & ConditionsPrivacy PolicyCareersSitemapContent Management Website Newcastle |
|
|
|
